Transitioning from preclinical to clinical chemopreventive assessments of lyophilized black raspberries: Interim results show berries modulate markers of oxidative stress in Barrett's esophagus patients

Nutrition and Cancer

Volumn 54, Issue 1, 2006, Pages 148-156

  Kresty, Laura A ^a,b   Frankel, Wendy L ^a   Hammond, Cynthia D ^a   Baird, Maureen E ^a   Mele, Jennifer M ^a   Stoner, Gary D ^a   Fromkes, John J ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTAGLANDIN F2 ALPHA;

ADULT; AGED; BARRETT ESOPHAGUS; CANCER RECURRENCE; CANCER RISK; CELL CULTURE; CLINICAL ARTICLE; COLON CARCINOGENESIS; CONFERENCE PAPER; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FEMALE; FOOD INTAKE; FRUIT; HUMAN; MALE; MOUTH CANCER; OXIDATIVE STRESS; PRECANCER; RASPBERRY; VEGETABLE;

AGED; ANTICARCINOGENIC AGENTS; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; DEOXYGUANOSINE; DINOPROST; ESOPHAGEAL NEOPLASMS; FEMALE; FOOD PRESERVATION; FREEZE DRYING; FRUIT; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHYTOTHERAPY; PILOT PROJECTS; PRECANCEROUS CONDITIONS; ROSACEAE;

ANIMALIA; RUBUS OCCIDENTALIS;

EID: 33645090336     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5401_15     Document Type: Conference Paper

References (57)

1. Huang C, Huang Y, Li J, Hu W, Aziz R, et al.: Inhibition of benzo(a)pyrene diol-epoxide-induced transactivation of activated protein I and nuclear factor κB by black raspberry extracts. Cancer Res 62, 6857-6863, 2002.
2. Han C, Ding H, Casto B, Stoner GD, and D'Ambrosio SM: Inhibition of the growth of premalignant and malignant human oral cell lines by extracts and components of black raspberries. Nutr Cancer 51, 207-217, 2005.
3. Kresty LA, Morse MA, Morgan C, Carlton PS, Lu J, et al.: Chemoprevention of esophageal tumorigenesis by dietary administration of lyophilized black raspberries. Cancer Res 61, 6112-6119, 2001.
4. Harris GK, Carlton PS, Liston BW, Gupta AK, Nines RG, et al.: Effects of lyophilized black raspberries on azoxymethane-induced colon cancer and 8-hydroxy-2′-deoxyguanosine levels in the Fischer 344 rat. Nutr Cancer 40, 125-133, 2001.
5. Casto BC, Kresty LA, Kraly CL, Pearl DK, Knobloch TJ, et al.: Chemoprevention of oral cancer by black raspberries. Anticancer Res 22, 4005-4016, 2002.
6. Cameron AJ, Ott BJ, and Payne WS: The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313, 857-859, 1985.
7. Haggitt RC: Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25, 982-993, 1994.
8. Spechler SJ: Barrett's esophagus. N Engl J Med 346, 836-842, 2002.
9. Blot WJ, Devesa SS, and Fraumeni JF: Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 270, 1320, 1993.
10. Lagergren J, Bergstrom R, Lindgren A, and Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340, 825-831, 1999.
11. Reid BJ: Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 20, 817-834, 1991.
12. Shaheen NJ, Crosby MA, Bozymski EM, and Sandler RS: Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119, 333-338, 2000.
13. Spechler SJ and Goyal RK: Barrett's esophagus. N Engl J Med 315, 362-371, 1986.
14. Wild CP and Hardie LJ: Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev 3, 676-684, 2003.
15. Beilstein M and Silberg D: Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma. Gastroenterol Clin North Am 31, 461-479, 2002.
16. Chen X and Yang CS: Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 22, 119-129, 2001.
17. Wetscher GJ, Hinder RA, Bagchi D, Hinder PR, Bagchi M, et al.: Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg 170, 552-557, 1995.
18. Sihvo EIT, Salminen JK, Rantanen TK, Ramo OJ, Ahotupa M, et al.: Oxidative stress has a role in malignant transformation in Barrett's esophagus. Int J Cancer 102, 551-555, 2002.
19. Janssen AML, Bosman CB, van Duijn W, Oostendorp-van de Ruit MM, Kubben FJGM, et al.: Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. Clin Cancer Res 6, 3183-3192, 2000.
20. Farhadi A, Fields J, Banan A, and Keshavarzian A: Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer? Am J Gastroenterol 97, 22-26, 2002.
21. Chen X, Ding YW, Yang G-Y, Bondoc F, Lee M-J, et al.: Oxidative damage in the esophageal adenocarcinoma model with rats. Carcinogenesis 21, 257-263, 2000.
22. Olliver JR, Hardie LJ, Gong Y-Y, Dexter S, Chalmers D, et al.: Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 14, 620-625, 2005.
23. Olliver JR, Hardie LJ, Dexter S, Chalmers D, and Wild CP: DNA damage levels are raised in Barrett's oesophageal mucosa relative to the squamous epithelium of the esophagus. Biomarkers 8, 509-521, 2003.
24. Fountoulakis A, Martin IG, White KL, Dixon MF, Cade JE, et al.: Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus. Dig Dis Sci 49, 914-919, 2004.
25. American Cancer Society: Cancer Facts & Figures, 2005. Atlanta, GA: American Cancer Society, 2005.
26. Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, et al.: Risk factors for Barrett's esophagus: a case control study. Int J Cancer 97, 225-229, 2002.
27. Lagergren J, Bergstrom R, Lindgren A, and Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340, 825-831, 1999.
28. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, et al.: Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. JNCI 90, 150-155, 1998.
29. Provenzale D, Kemp JA, Arora S, and Wong JB: A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 89, 670-680, 1994.
30. Lagergren J, Bergstrom R, and Nyren O: Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130, 883-890, 1999.
31. Calle EE, Rodriguez C, Walker-Thurmond K, and Thun M: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348, 1625-1638, 2003.
32. Wu AH, Wan P, and Berstein LA: Multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus. Cancer Causes Control 12, 721-732, 2001.
33. Engeland A, Tretli S, and Bjørge T: Height and body mass index in relation to esophageal cancer; 23-year follow-up of two million Norwegian men and women. Cancer Causes Control 15, 837-843, 2004.
34. Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, et al.: Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 11, 745-752, 2002.
35. Moe GL, Kristal AR, Levine DS, Vaughan TL, and Reid BJ: Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content cytometry in Barrett's esophagus. Nutr Cancer 36, 7-13, 2000.
36. Mayne ST and Navarro SA: Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 132, S3467-S3470, 2002.
37. Terry P, Lagergren J, Ye W, Wolk A, and Nyren O: Inverse association between intake of cereal fiber and risk of gastric cardia cancer. Gastroenterology 120, 387-391, 2001.
38. Mayne ST, Risch HA, Dubrow R, Chow W-H, Gammon MD, et al.: Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 10, 1055-1062, 2001.
39. Chen H, Tucker KL, Graubard BI, Heineman EF, Markin RS, et al.: Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr Cancer 42, 33-40, 2002.
40. Engel LS, Chow W-H, Vaughan TL, Gammon MD, Risch HA, et al.: Population attributable risks of esophageal and gastric cancers. JNCI 95, 1404-1413, 2003.
41. Ou B, Hampsch-Woodill M, and Prior RL: Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J Agric Food Chem 49, 4619-4626, 2001.
42. Huang D, Ou B, Hampsch-Woodill M, Flanagan JA, and Prior RL: High-throughput assay of oxygen radical absorbance capacity (ORAC) using a multichannel liquid handling system coupled with a microplate fluorescence reader in 96-well format. J Agric Food Chem 50, 4437-4444, 2002.
43. Yin B, Whyatt RM, Perera FP, Randall MC, and Cooper TB: Determination of 8-hydroxydeoxyguanosine by an immunoaffinity chromatography-monoclonal antibody-based ELISA. Free Radic Biol Med 18, 1023-1032, 1995.
44. Wang Z, Ciabattoni G, Creminon C, Lawson J, and Fitzgerald GA: Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 275, 94-100, 1995.
45. Yamazaki H, Inoue T, Koizumi M, Tanaka E, Yoshioka Y, et al.: Urinary 8-hydroxy-2′-deoxyguanosine excretion as a biomarker for estimating DNA oxidation in patients undergoing external radiotherapy and/or brachytherapy. Oncol Rep 13, 847-851, 2005.
46. Loft S and Poulsen HE: Estimation of oxidative DNA damage in man from urinary excretion of repair products. Acta Biochim Pol 45, 133-144, 1998.
47. Halliwell B: Antioxidants in human health and disease. Annu Rev Nutr 16, 33-50, 1996.
48. Valko M, Izakovic M, Mazur M, Rhodes CJ, and Telser J: Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 266, 37-56, 2004.
49. Musarrat J, Arezina-Wilson J, and Wani AA: Prognostic and aetiologic relevance of 8-hydroxyguanosine in human breast carcinogenesis. Euro Cancer 32A, 1209-1214, 1996.
50. Chiou CC, Chang PY, Chan EC, Wu TL, Tsao KC, et al.: Urinary 8-hydroxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 334, 87-94, 2003.
51. Miyake H, Hara I, Kamidono S, and Eto H: Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol 171, 1533-1536, 2004.
52. Cooke MS, Evans MD, Herbert KE, and Lunec J: Urinary 8-oxy-2′- deoxyguanosinesource, significance and supplements. Free Radic Res 32, 381-397, 2000.
53. Basu S and Helmersson J: Factors regulating isoprostane formation in vivo. Antioxid Redox Signal 7, 221-235, 2005.
54. Montuschi P, Barnes PJ, and Roberts LJ: Isoprostanes: markers and mediators of oxidative stress. FASEB J 18, 1791-1800, 2004.
55. Clements DM, Oleesky DA, Smith SC, Wheatley H, Hullin DA, et al.: A study to determine plasma antioxidant concentrations in patients with Barrett's oesophagus. J Clin Pathol 58, 490-492, 2005.
56. Cobbe SC, Scobie GC, Pohler E, Hayes JD, Kernohan NM, et al.: Alteration of glutathione S-transferase levels in Barrett's metaplasia compared to normal oesophageal epithelium. Eur J Gastroenterol Hepatol 1, 41-47, 2003.
57. Brabender J, Lord RV, Wickramasinghe K, Metzger R, Schneider PM, et al.: Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg 6, 359-367, 2002.